Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Notes Payables (2017 - 2025)

Historic Notes Payables for vTv Therapeutics (VTVT) over the last 10 years, with Q3 2025 value amounting to $328000.0.

  • vTv Therapeutics' Notes Payables changed N/A to $328000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $328000.0, marking a year-over-year change of. This contributed to the annual value of $191000.0 for FY2023, which is 1473.21% down from last year.
  • Latest data reveals that vTv Therapeutics reported Notes Payables of $328000.0 as of Q3 2025.
  • Over the past 5 years, vTv Therapeutics' Notes Payables peaked at $636000.0 during Q3 2021, and registered a low of $191000.0 during Q4 2023.
  • Over the past 4 years, vTv Therapeutics' median Notes Payables value was $328000.0 (recorded in 2025), while the average stood at $380714.3.
  • Over the last 5 years, vTv Therapeutics' Notes Payables had its largest YoY gain of 20476.19% in 2021, and its largest YoY loss of 7315.32% in 2021.
  • Over the past 4 years, vTv Therapeutics' Notes Payables (Quarter) stood at $256000.0 in 2021, then fell by 12.5% to $224000.0 in 2022, then dropped by 14.73% to $191000.0 in 2023, then surged by 71.73% to $328000.0 in 2025.
  • Its Notes Payables stands at $328000.0 for Q3 2025, versus $191000.0 for Q4 2023 and $473000.0 for Q3 2023.